Skip to main content
Caplight Logo









D-Sight

D-Sight

Private
BarcelonaHealthcare & Life Scienceshttps://www.dsight.es/

Last Round

VC Round

Feb 23, 2026

Total Funding Raised

$1.08M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

D-Sight is a biotechnology company developing neuroprotective eye drops for the treatment of retinal neurodegenerative diseases such as diabetic retinopathy and glaucoma.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyneuroprotective eye dropsretinal neurodegenerationdiabetic retinopathyglaucoma treatmenteye drop therapyclinical-stage biotechdrug discoveryophthalmologynon-invasive therapyeye healthbiotech spin-offtherapeutic drug candidateeye dropsvision care

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

D-Sight Comparables

Compare D-Sight with similar companies based on industry and business-model similarity.

D-Sight comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Aspecthera Pty Ltd
86%
Exonate
84%
Glucox Biotech AB
84%

D-Sight Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundFeb 23, 2026
SeedMay 2, 2023

Key People

Founding team and executive leadership

Carla Maté Goldar

Chief Executive Officer and co-founder

Founding Team

D-Sight Investors

Notable investors and investment history

D-Sight investors
InvestorRounds
Prous Institute for Biomedical ResearchVC Round
Clave CapitalVC Round, Seed
Catalan Institute of FinanceVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 23, 2026

    $2.36M round led by Clave Capital.

  • Feb 2, 2026

    Monthly visitors grew 36% MoM, reaching 1.3K.

D-Sight Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

D-Sight Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about D-Sight's valuation, stock price, and market status.

Firmographic Details

HeadquartersBarcelona
Employee Range3
Year Founded2023
Last FundingFeb 23, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?